Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO

Published on 11/19/2024 at 19:31 - Modified on 11/19/2024 at 19:39

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma Unit Cuts Stake in Suzhou Angel Fund Capital; Shares Rise 6%	Jul. 16	MT
Shanghai Fosun Pharma says all partners of Suzhou Angel Fund resolved to conduct proportional capital reduction	Jul. 15	RE
Shanghai Fosun Pharma updates on Polyethylene Glycol Electrolytes Powder	Jul. 11	RE
Fosun Pharma Unit's Registration Application for Bowel Cleansing Drug Accepted by Chinese Regulator	Jul. 11	MT
Fosun Pharma Unit Launches Phase III Trial for Luvometinib Tablets; Shares Up 1%	Jul. 09	MT
Nature's Sunshine Shares Fall Premarket After Shanghai Fosun Sells Stake	Jun. 26	DJ
Fosun Pharma Names CEO	Jun. 24	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Management Changes	Jun. 24	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Committee Changes, Effective June 24, 2025	Jun. 24	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Announces CEO Changes, Effective June 24, 2025	Jun. 24	CI
Shanghai Fosun Pharmaceutical Co., Ltd.(SHSE:600196) dropped from Shanghai Stock Exchange 180 Value Index	Jun. 22	CI
Fosun Pharma Repurchases Over 1 Million Shares	Jun. 18	MT
Teva And Fosun Pharma Enter Into A Strategic Partnership To Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) In Immuno-Oncology	Jun. 16	RE
ImmuneOnco Biopharmaceuticals Names Chief Medical Officer	Jun. 09	MT
Immuneonco Biopharmaceuticals Inc. Appoints Dr. Wu Zhuli as A Chief Medical Officer as Chief Medical Officer, Effect from June 9, 2025	Jun. 09	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Elects Ms. Yan Jia as Employee Director of the Tenth Session of the Board	Jun. 06	CI
Fosun Pharma's Respiratory Drug Receives Clinical Trial Approval for COPD Treatment in China	Jun. 02	MT
Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd. Launches the Phase II Clinical Trial on Xh-S004 Tablets	May. 30	CI
Fosun Pharmaceutical Gets Chinese Regulatory Approval for Tumor Drug; Shares Up 4%	May. 29	MT
Fosun Pharmaceutical Gets Chinese Regulatory Approval for Breast Cancer Drug; Shares Up 4%	May. 29	MT
Jinzhou Avanc Pharmaceutical Co., Ltd. Announces Approval for Drug Registration of Subsidiary	May. 29	CI
Shanghai Fosun Pharma Says NMPA Approved Drug Registration Application For Fovinaciclib Citrate Capsules	May. 29	RE
Shanghai Fosun Pharma Says NMPA Approved Drug Registration Application For Luvometinib Tablets	May. 29	RE
Fosun Pharmaceutical Gains EU Orphan Drug Status for Cancer Drug	May. 27	MT
Shenzhen Salus Medical Technology Co., Ltd. announced that it has received funding from Shanghai Fosun Pharmaceutical Co., Ltd., Changzhou Weichi Equity Fund Management Co., Ltd., Shenzhen Capital Group Co., Ltd.	May. 13	CI